Retefuse 18mg Injection
By Retefuse
Rx
1 Injection in a Packet

Composition
Reteplase(18mg)

Manufacturer - Lupin Ltd
Lupin Ltd, 3rd floor Kalpataru Inspire, Off. W E Highway, Santacruz (East), Mumbai 400 055. India

Expires on or after
May, 2026

liver
When using Retefuse 18mg Injection, it is important to be cautious if you have liver disease. Patients with liver issues may require a dose adjustment for this medication. It is advised to consult your doctor before starting treatment with Retefuse 18mg Injection. It is not recommended to use this injection in individuals with severe kidney disease.

kidney
Retefuse 18mg Injection needs caution in patients with kidney disease. Dose adjustment may be necessary; consult your doctor. Not recommended for severe kidney disease patients.

alcohol
Consult your doctor when consuming alcohol with Retefuse 18mg Injection.

driving
It is better to consult your doctor. Refrain from driving if you have symptoms impairing focus and reaction time when using Retefuse 18mg Injection.

pregnancy
Retefuse 18mg Injection is considered unsafe during pregnancy. Animal studies have shown potential harm to the developing baby. Your doctor will evaluate the benefits and risks before prescribing. Kindly consult your doctor before use.

breastfeeding
Retefuse 18mg Injection is likely safe while breastfeeding, as minimal human data indicates low risk to the baby.
Habit Forming | No |
Chemical Class | Carboxylic Acid Derivative |
Therapeutic Class | - |
Action Class | Plasminogen Activators- Thrombolytics |
₹32650
Inclusive of all taxes
Content verified by

Dr. Abdullah Khan
MBBS - General Medicine
Last update on 01-Oct-2024